List of Excipients in Branded Drug SUSTIVA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bristol-Myers Squibb Pharma Company	SUSTIVA	efavirenz	0056-0470	FD&C BLUE NO. 2
Bristol-Myers Squibb Pharma Company	SUSTIVA	efavirenz	0056-0470	FERRIC OXIDE YELLOW
Bristol-Myers Squibb Pharma Company	SUSTIVA	efavirenz	0056-0470	GELATIN
Bristol-Myers Squibb Pharma Company	SUSTIVA	efavirenz	0056-0470	LACTOSE MONOHYDRATE

Sustiva Excipient Strategy and Commercial Opportunities for Efavirenz

Last updated: August 9, 2026

Sustiva is the brand name for efavirenz, a non-nucleoside reverse transcriptase inhibitor approved by the FDA in 1998 for use in combination antiretroviral therapy. Its formulation strategy centers on managing efavirenz’s poor aqueous solubility, high lipophilicity, food effect, dose uniformity, and capsule or tablet manufacturability. The core commercial opportunity is now generic and differentiated formulation development rather than branded-product exclusivity.

Efavirenz is available as 50 mg, 100 mg, and 200 mg capsules and as a 600 mg film-coated tablet. The active ingredient is a low-dose, poorly water-soluble small molecule, making excipient selection important for dissolution, exposure, stability, and scale-up. Conventional generic products face limited patent barriers, while improved pediatric, fixed-dose, long-acting, and high-stability formulations offer the strongest remaining opportunities.

What excipients are used in Sustiva formulations?

Sustiva uses a conventional solid oral excipient system based on lactose, cellulose derivatives, sodium lauryl sulfate, magnesium stearate, and capsule or film-coating materials.

Product	Strengths	Principal inactive ingredients reported in labeling
Sustiva hard capsules	50 mg, 100 mg, 200 mg	Lactose, cellulose-based diluent or binder, sodium lauryl sulfate, magnesium stearate, talc, gelatin, titanium dioxide, and strength-specific colorants
Sustiva film-coated tablets	600 mg	Lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, cellulose-based coating or binder materials, sodium lauryl sulfate, magnesium stearate, titanium dioxide, and colorants
Generic efavirenz products	Usually 50 mg, 100 mg, 200 mg, and 600 mg	Product-specific combinations of lactose, microcrystalline cellulose, starches, croscarmellose sodium, sodium lauryl sulfate, magnesium stearate, hypromellose, talc, and film-coating pigments

The exact composition varies by strength and manufacturer. FDA labeling identifies the inactive ingredients relevant to the marketed Sustiva products, while the FDA Inactive Ingredient Database provides broader precedent for excipient use in approved oral products.[1][2]

Why does Sustiva use sodium lauryl sulfate?

Sodium lauryl sulfate, or SLS, is a surfactant. It can improve wetting and dispersion of hydrophobic efavirenz particles, supporting dissolution in aqueous media. Efavirenz has very low water solubility and belongs to the class of compounds for which dissolution can limit oral absorption.

SLS also has manufacturing advantages. It can improve blend uniformity and reduce variability when the active ingredient is present at a relatively low proportion of the total tablet or capsule fill. Its limitations include potential gastrointestinal irritation, sensitivity to processing conditions, and compatibility concerns with some excipients or coating systems.

A generic manufacturer can therefore pursue either:

1. A direct excipient match using SLS.
2. A reduced-SLS or SLS-free formulation using particle-size control, wetting agents, surfactant blends, or solid-dispersion technology.
3. A formulation that improves dissolution without materially increasing systemic exposure beyond the reference product.

What technical problems must an efavirenz formulation solve?

Efavirenz presents four main formulation challenges.

Low aqueous solubility

Efavirenz is lipophilic and poorly soluble in water. Dissolution rate can vary with particle size, polymorphic form, crystallinity, compression force, wetting, and gastrointestinal conditions.

A formulation that produces rapid dissolution in a standard medium may not perform consistently under fed and fasted conditions. The development target is therefore not simply maximum dissolution. It is reproducible bioavailability consistent with the reference product.

Food-related exposure changes

The Sustiva label reports increased efavirenz exposure after a high-fat meal. The label recommends administration on an empty stomach, preferably at bedtime, to reduce central nervous system effects and manage food-related exposure variability.[1]

This creates an excipient and commercial opportunity. A formulation that reduces sensitivity to meal composition could offer adherence advantages, although it would require clinical or pharmacokinetic evidence and careful control of total exposure.

Dose uniformity and powder behavior

Efavirenz’s low dose relative to total dosage-unit mass can create blend segregation and content-uniformity risks. Particle engineering, geometric dilution, granulation, ordered mixing, and controlled lubrication are relevant process tools.

The 600 mg tablet presents a different problem. It requires a large unit dose with acceptable tablet size, hardness, friability, disintegration, and swallowability. The 50 mg to 200 mg capsules require reliable powder filling and color or strength differentiation.

Stability and supply-chain conditions

HIV medicines are distributed in regions with high heat, humidity, and variable storage infrastructure. Excipient systems should support chemical and physical stability under International Council for Harmonisation conditions and, where relevant, extended stability programs for tropical markets.

Moisture-sensitive disintegrants, hygroscopic binders, capsule shell brittleness, and coating defects can affect commercial performance. Aluminum-aluminum blister packaging, high-barrier bottles, desiccants, and moisture-protective film coatings may be as commercially important as the core excipient choice.

What formulation strategies are available for generic efavirenz?

Conventional immediate-release tablets and capsules

This is the lowest-risk strategy for an ANDA applicant. A manufacturer can use the same dosage forms and strengths as Sustiva, apply a conventional Q1/Q2-style excipient approach where feasible, and demonstrate pharmaceutical equivalence, dissolution similarity, and bioequivalence.

The advantages are:

• Established manufacturing processes.
• Lower development cost.
• Familiar regulatory pathway.
• Broad availability of excipient precedent.
• Compatibility with existing HIV procurement channels.

The disadvantage is limited differentiation. Price, manufacturing reliability, regulatory approvals, and tender access become the primary competitive variables.

Micronized efavirenz

Particle-size reduction can increase surface area and improve dissolution without changing the active chemical entity. Micronization is compatible with conventional tablets and capsules, but it introduces control requirements for particle-size distribution, electrostatic behavior, agglomeration, and blend uniformity.

The key intellectual property opportunity is process protection around particle engineering, milling conditions, crystallization, or a controlled polymorphic form. Such claims must be assessed against prior art and the expired foundational efavirenz patents.

Amorphous solid dispersions

Amorphous solid dispersions can improve apparent solubility and dissolution by dispersing efavirenz in a polymeric carrier such as hydroxypropyl methylcellulose, hypromellose acetate succinate, or polyvinylpyrrolidone-based materials.

Potential benefits include:

• Higher dissolution rate.
• Lower reliance on SLS.
• Possible reduction in food sensitivity.
• Compatibility with lower-dose pediatric products.

Risks include recrystallization, polymer moisture uptake, physical instability, scale-up complexity, and higher cost. The formulation must maintain supersaturation long enough to improve absorption rather than merely produce rapid in vitro dissolution.

Nanocrystals and nanosuspensions

Efavirenz nanocrystals can improve dissolution and may support liquid or solid dosage forms. The technology is technically attractive for pediatric and low-volume products, but commercial complexity is higher. Stabilizer selection, particle growth, redispersibility, sterile manufacturing for injectable concepts, and long-term physical stability must be controlled.

For oral efavirenz, nanocrystal technology is more commercially plausible in a pediatric suspension or dispersible solid than in a standard adult tablet, where the price premium may not be justified.

Lipid-based systems

Self-emulsifying drug delivery systems and other lipid formulations can improve solubilization of lipophilic efavirenz. They may reduce dissolution dependence, but they add excipient burden, packaging requirements, and potential food-effect interactions.

Lipid systems are most attractive where the product targets difficult-to-treat pediatric populations, patients with swallowing limitations, or a differentiated fixed-dose combination. They are less attractive for low-cost adult generics unless they deliver a measurable pharmacokinetic or adherence benefit.

Taste-masked pediatric formulations

Efavirenz has a strong taste profile that complicates liquid and dispersible dosage forms. Pediatric formulations require taste masking through polymer coating, ion exchange, complexation, microencapsulation, or flavor systems.

A successful product would need:

• Acceptable palatability.
• Dose flexibility.
• Low administration volume.
• Stability after reconstitution, if applicable.
• Compatibility with antiretroviral coadministration.
• Minimal food or beverage interaction.

Pediatric formulation development is commercially relevant because the WHO has supported age-appropriate HIV dosage forms, while adult efavirenz demand has declined as dolutegravir-based treatment has become preferred in many guidelines.[3]

What commercial opportunities exist for efavirenz excipient innovation?

Which efavirenz products have the strongest commercial potential?

Opportunity	Technical value	Commercial attractiveness	Primary barrier
Low-cost conventional generic	Reliable supply and low price	High in tender markets	Intense price competition
Heat- and humidity-stable tablet	Better distribution resilience	Moderate to high	Packaging and stability cost
Pediatric dispersible tablet	Flexible dosing and improved administration	High in selected markets	Palatability and clinical positioning
Taste-masked oral suspension	Useful for young children or swallowing-limited patients	Moderate	Stability, dosing accuracy, and taste
SLS-free formulation	Potential tolerability and clean-label positioning	Low to moderate	Need to match dissolution and exposure
Amorphous dispersion	Potential bioavailability improvement	Moderate	Physical stability and scale-up
Fixed-dose combination	Lower pill burden	Moderate	Combination compatibility and market demand
Long-acting efavirenz formulation	Reduced dosing frequency	Low to moderate	Clinical development and competitive displacement

The most practical opportunity is a robust generic platform with multiple strengths, pediatric flexibility, and stability suited to public-sector procurement. A premium formulation must overcome the fact that efavirenz is increasingly displaced by dolutegravir in first-line HIV treatment.

Can an excipient strategy support fixed-dose combinations?

Efavirenz has been used in combinations with tenofovir disoproxil fumarate and emtricitabine, including once-daily regimens. Fixed-dose combinations create excipient challenges because the active ingredients have different particle properties, dose loads, compression behavior, and dissolution requirements.

A successful formulation may use:

• Bilayer or multilayer tablet architecture.
• Separate granulation of incompatible actives.
• Functional coatings.
• Controlled particle-size distributions.
• Disintegrant optimization.
• Moisture-protective packaging.

The commercial opportunity is strongest in markets where efavirenz-based regimens remain part of procurement portfolios, including treatment continuity, substitution, and certain pregnancy or drug-interaction scenarios. Market access depends on WHO prequalification, national registration, and tender eligibility rather than only on technical performance.

What is the FDA regulatory status of Sustiva and generic efavirenz?

The FDA approved Sustiva in 1998. Efavirenz is a small-molecule drug, so generic products use the ANDA pathway rather than the biosimilar pathway. There is no biosimilar category for efavirenz.

A generic applicant generally must establish:

• Pharmaceutical equivalence.
• Bioequivalence to the reference listed drug.
• Assay and content uniformity.
• Comparative dissolution.
• Stability.
• Manufacturing controls.
• Labeling consistent with the reference product, subject to permitted differences.

Excipients do not need to be identical in every case. They must be suitable for the dosage form, supported by safety precedent or appropriate qualification, and shown not to compromise product performance.

When does Sustiva lose exclusivity, and what is the Orange Book status?

Sustiva’s original market exclusivity and foundational patent protection have expired. The product has been commercially exposed to generic competition for many years. FDA Orange Book analysis is therefore more relevant to confirming residual listed patents or exclusivity than to identifying a likely branded barrier to entry.[4]

Are Paragraph IV challenges relevant to efavirenz?

Paragraph IV certifications were commercially relevant during the historical generic-entry period, when applicants challenged listed patents as invalid, unenforceable, or not infringed. Current efavirenz opportunities are generally based on an expired or substantially cleared patent estate rather than a new Paragraph IV strategy.

For a new formulation, patent risk may still arise from:

• Crystalline or polymorphic forms.
• Amorphous dispersions.
• Particle-size specifications.
• Pediatric dosage forms.
• Fixed-dose combinations.
• Manufacturing processes.
• Specific excipient combinations.
• Method-of-use claims.

The commercial value of such patents depends on whether the formulation creates clinically meaningful differentiation. A formulation patent covering a narrow excipient combination may have limited enforceability if a competitor can obtain equivalent performance with a different composition.

How strong is the efavirenz patent estate?

The original efavirenz composition and pharmaceutical patents are no longer a durable barrier to conventional generic tablets and capsules. The remaining strategic value is concentrated in later, formulation-specific or process-specific filings, if enforceable claims remain in the relevant jurisdiction.

Patent category	Relevance to current entry	Typical risk
Original efavirenz compound claims	Low after expiration	Minimal for ordinary generics
Conventional tablet or capsule claims	Low to moderate	Depends on surviving formulation claims
Polymorph or crystalline-form claims	Moderate	Can affect solid-state replication
Amorphous dispersion claims	Moderate	Claim scope and prior-art exposure
Pediatric formulation claims	Moderate	Relevant to differentiated products
Fixed-dose combination claims	Moderate	Combination-specific validity and market demand
Manufacturing-process claims	Low to moderate	Avoidable through process design
Method-of-use claims	Low for broad adult use	More relevant in narrow populations

Geographic coverage must be assessed separately. Patent expiry, supplementary protection, pediatric extensions, data exclusivity, and litigation outcomes vary by jurisdiction. The United States and European markets are more mature, while procurement markets may prioritize registration, price, and supply capacity.

Which companies are challenging or competing with Sustiva?

Competition comes mainly from generic manufacturers and suppliers of alternative antiretroviral regimens. The principal competitive groups include:

• Large generic pharmaceutical companies with efavirenz ANDAs.
• Indian manufacturers supplying global HIV programs.
• Public-sector and donor-supported suppliers.
• Manufacturers of tenofovir, lamivudine, and efavirenz fixed-dose combinations.
• Suppliers of dolutegravir-based alternatives.

Dolutegravir has reduced the strategic importance of efavirenz in many first-line treatment settings because of superior efficacy, resistance characteristics, and guideline preference. Efavirenz remains commercially relevant where patients are stable on existing therapy, where procurement systems maintain legacy regimens, or where specific clinical and supply considerations support continued use.[3]

What generic launch scenarios exist for efavirenz?

Low-price adult generic

This scenario uses conventional excipients, standard strengths, high-volume manufacturing, and public procurement. Success depends on cost of goods, regulatory approvals, quality history, and tender execution.

Differentiated pediatric product

This scenario uses taste masking, dispersibility, dose flexibility, and packaging suited to low-resource settings. It can command better strategic value but requires stronger clinical, palatability, and market-access evidence.

Fixed-dose combination replacement

A manufacturer can target continuity markets where efavirenz combinations remain established. The product must match the required strength, dissolution profile, stability, and regulatory standards for each active ingredient.

Regional supply platform

A manufacturer can use one excipient and process platform across multiple strengths and countries. The value comes from manufacturing efficiency, reduced change-control burden, and consistent regulatory documentation.

Key Takeaways

• Sustiva contains efavirenz, a poorly water-soluble, lipophilic small molecule that requires excipient support for wetting, dissolution, blend uniformity, and stability.
• The reference formulation uses conventional excipients, including lactose, cellulose-based materials, sodium lauryl sulfate, magnesium stearate, and coating or capsule-shell components.
• Conventional generic tablets and capsules face limited patent barriers because foundational efavirenz exclusivity has expired.
• The strongest technical opportunities are micronized efavirenz, SLS-reduced formulations, amorphous dispersions, pediatric taste masking, and heat- and humidity-stable products.
• The strongest commercial opportunity is a cost-efficient, globally registrable platform with pediatric or fixed-dose-combination capability.
• Efavirenz demand faces structural pressure from dolutegravir-based regimens.
• Efavirenz is a small molecule and does not create a biosimilar market.
• Current patent value is concentrated in formulation, polymorph, process, pediatric, and combination claims rather than the original active-ingredient estate.

FAQs

Can lactose be removed from a generic efavirenz formulation?

Yes. A generic manufacturer can replace lactose with microcrystalline cellulose, mannitol, starch, dibasic calcium phosphate, or another suitable diluent, provided the formulation meets pharmaceutical-equivalence, dissolution, bioequivalence, stability, and safety requirements.

Is an SLS-free efavirenz tablet commercially viable?

It can be viable, particularly if particle-size engineering, a different surfactant, or a solid-dispersion approach maintains dissolution and exposure. The commercial case is stronger for pediatric or differentiated products than for commodity adult tablets.

Does efavirenz require a solubility-enhancing excipient?

Not necessarily. The approved product uses a conventional immediate-release system, but solubility-enhancing excipients can improve dissolution robustness and may support differentiated products. Any improvement must remain within the bioequivalence and exposure profile required for the reference product.

Are efavirenz formulation patents still important outside the United States?

They can be. Patent term, national filings, supplementary protection, and enforcement outcomes differ by country. A product cleared in the United States may still require country-specific freedom-to-operate analysis in Europe, Asia, Latin America, and other regulated or procurement markets.

What is the best excipient platform for an efavirenz pediatric product?

A taste-masked, dispersible solid dosage form is generally more commercially practical than a conventional liquid. It can reduce shipping volume, improve stability, support flexible dosing, and avoid some of the microbial and physical-stability issues associated with aqueous suspensions.

References

1. U.S. Food and Drug Administration. (2016). Sustiva (efavirenz) prescribing information. Bristol-Myers Squibb Company.

2. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

3. World Health Organization. (2021). Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: Recommendations for a public health approach. World Health Organization.

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm